KR920014804A - 아릴 (또는 헤테로아릴) 피페라지닐알킬아졸 유도체 및 그의 제조방법 및 그의 의약품으로의 이용 - Google Patents

아릴 (또는 헤테로아릴) 피페라지닐알킬아졸 유도체 및 그의 제조방법 및 그의 의약품으로의 이용 Download PDF

Info

Publication number
KR920014804A
KR920014804A KR1019920001213A KR920001213A KR920014804A KR 920014804 A KR920014804 A KR 920014804A KR 1019920001213 A KR1019920001213 A KR 1019920001213A KR 920001213 A KR920001213 A KR 920001213A KR 920014804 A KR920014804 A KR 920014804A
Authority
KR
South Korea
Prior art keywords
butyl
piperazinyl
pyrimidinyl
formula
compound
Prior art date
Application number
KR1019920001213A
Other languages
English (en)
Other versions
KR0135969B1 (ko
Inventor
메르쎄 비달 라몬
프리글라-콘스탄샤 조르디
빠레스-꼬로미나스 쥬앙
Original Assignee
마뇨사스 바레라, 엔리께
라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마뇨사스 바레라, 엔리께, 라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마 filed Critical 마뇨사스 바레라, 엔리께
Publication of KR920014804A publication Critical patent/KR920014804A/ko
Application granted granted Critical
Publication of KR0135969B1 publication Critical patent/KR0135969B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

내용 없음

Description

아릴 (또는 헤테로아릴) 피페라지닐알킬아졸 유도체 및 그의 제조방법 및 그의 의약품으로의 이용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 히기의 일반식(Ⅰ)을 가지는 것을 특징으로 하는 복소환식 화합물.
    상기의 일반식에서, Ar은 질소를 포함하거나 포함하지 않으며, 다른 치환체를 가진 아릴류, 2-피리미딘, 2-N-메틸이미다졸 및 3-(1,2-벤즈이소트리아졸)로부어 선택되어지는 방향족 리디킬을 나타내며, n은 1 내지 6의 값, Z1은 질소원자 또는 C-R1기, Z2는 질소원자 또는 C-R2기, Z4는 질소원자 또는 C-R4기, Z5는 질소원자 또는 탄소원자, Z6는 아자기 또는 치환되거나 치환되지 않은 메틸렌기를 나타내는데 Z5가 질소원자일 경우에는 Z6는 메틸렌기, Z5가 탄소원자일 경우에는 Z6는 치환되거나 치환되지 않은 아자기를 나타낸다. R1, R2, R3, R4는 동일하거나 다를 수 있으며, 또다른 방향족 또는 비방향족 고리르 형성할 수도 있다. R1, R2, R3, R4는 수소원자, 할로겐, 저급 알킬 라디칼, 히드록실 라디칼, 카르복실 라디칼, 카르복스아미도 라디칼, 알킬카르복실레이트라디칼 또는 아릴 또는 치환된 아릴 라디칼을 나타내는데, Ar이 2-피리미딘이고, Z6가 치환되거나 치환되지 않은 메틸렌기일 때 Z1내지 Z6은 모두 3치환된 이미다졸, 치환되거나 치환되지 않은 벤즈이미다졸 및 치환되거나 치환되지 않은 이미다조피리딘으로 구성된 그룹으로부터 선택되는 복소환식 방향족 라디칼 및 그들의 제약학적으로 수용가능한 산부가염을 나타낸다. 다만, 여기서 Ar이 치환되거나, 치환되지 않는 페닐기이고, Z2및 Z5가 모두 질소원자, Z1이 C-R1기, Z4는 C-R4기, R3-R4가 또다른 방향족 고리를 형성하는 화합물은 제외된다.
  2. 제1항에 있어서, 상기 일반식(Ⅰ)이 하기의 군으로부터 선택되는 것을 특징으로 하는 복소환식 화합물 1) 1-{4-[4-(2-피리미디닐)-1-페페라지닐]-부틸}-피롤 2) 1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-카아바졸 3)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-인돌 4) 2,3-디페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-인돌 5) 2,4,5-트리페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸 6) 4,5-디페닐-2메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸 7) 4,5-디클로로-2-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸 8) 4-페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸 9) 1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이미다졸 10)1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-3H-이미다조[5,4-b]피리미딘 11) 1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다조[4,5-b]피리미딘 12) 1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤조트리 아졸 13) 2-클로로 -1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이미다졸 14) 5-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이미다졸 15) 6-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈 이미다졸 16) 1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-1,2,4-트리아졸 17) 2-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-2H-벤조트리아졸 18) 2-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈이미다졸 19) 5,6-디메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-벤즈 이미다졸 20) 4-클로로-1-{4-[4-(4-메톡시페닐)-1-피페라지닐]-부틸}-1H-피라졸 21) 4,5-디클로로-2-메틸-1-{4-[4-(4-메톡시페닐)-1-피페라지닐]-부틸}-1H-이미다졸 22) 4-클로로-1-{4-[4-(2-메톡시페닐)-1-피페라지닐]-부틸}-1H-피라졸 23) 4,5-디클로로-2-메틸-1-{4-[4-(2-메톡시페닐)-1-피페라지닐]-부틸}-1H-이미다졸 24) 4-클로로-1-{4-[4-(2-메톡시페닐)-1-피페라지닐]-부틸}-1H-피라졸 25) 1-{4-[4-(4-메톡시페닐)-1-피페라지닐]-부틸}-피롤 26) 1-{4-[4-(2-메톡시페닐)-1-피페라지닐]-부틸}-피롤 27) 1-{4-[4-페닐-1-피페라지닐]-부틸}-피롤 28) 4-클로로-1-{4-[4-페닐-1-피페라지닐]-부틸}-1H-피라졸 29) 4,5-디클로로-2-메틸-1-{4-[4-페닐-1-피페라지닐]-부틸}-1H-이미다졸 30) 4-클로로-1-{4-[4-(2-클로로페닐)-1-피페라지닐]-부틸}-1H-피라졸 31) 4,5-디클로로-2-메틸-1-{4-[4-(2-클로로페닐)-1-피페라지닐]-부틸}-1H-이미다졸 32) 4-클로로-1-{4-[4-(3-클로로페닐)-1-피페라지닐]-부틸}-1H-피라졸 33) 1-{4-[4-(2-N-메틸이미다졸일)-1-피페라지닐]-부틸}-1H-피라졸 34) 4-클로로-1-{2-[4-(2-메톡시페닐)-1-피페라지닐]-부틸}-1H-피라졸 35) 4,5-디클로로-2-메틸-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-이미다졸 시트르산염 36) 4-클로로-1-{4-[4-(3-(1,2-벤즈이소트리아졸일)-1-피페라지닐]-부틸}-1H-피라졸 37) 4,5-디클로로-2메틸-1-{4-[4-(3-(1,2-벤즈이소트리아졸일)-1-피페라지닐]-부틸}-1H-이미다졸 38) 1,3{-디메틸-5-3-[4-(2-(메톡시페닐)-1-피페라지닐]-프로필아미노}-1H-피라졸.
  3. 하기 일반식(Ⅱ)의 화합물과 하기 일반식(Ⅲ)의 화합물의 반응을 포함하는 조작을 사용하는 것을 특징으로 하는 제1항 또는 제2항에 따른 화합물의 제조방법.
    상기 식에서 Ar및 n은 제1항에서와 같이 의미를 가지며, X는 할로겐 원자 또는 토실옥시나 메실옥시로부터 선택되는 이탈기를 나타낸다.
    상기 식에서 Z1, Z2, Z4및 R3는 제1항에서의 의미와 같다.
  4. 하기 일반식(Ⅳ)의 화합물과 하기 일반식(Ⅴ)의 화합물의 반응을 포함하는 조작을 사용하는 것을 특징으로 하는 제1항 또는 제2항에 따른 화합물의 제조방법.
    상기 식에서 Z1, Z2, Z4, Z5, Z6, Z3, n 및 X는 제1항에서의 의미와 같다.
    상기 식에서 Ar은 제1항에서의 의미와 같다.
  5. 하기 일반식(Ⅵ)의 화합물과 하기 일반식(Ⅶ)의 화합물의 반응을 포함하는 조작을 사용하는 것을 특징으로 하는 제1항 또는 제2항에 따른 화합물의 제조방법.
    상기 식에서 Z1, Z2, Z4, Z5, Z6, R3및 n은 제1항에서의 의미와 같다.
    Ar-X
    (Ⅶ)
    상기 식에서 Ar 및 X는 제1항에서의 의미와 같다.
  6. 하기 일반식(Ⅷ)의 화합물과 2,5-디메톡시테트라하이드로 퓨란과의 반응을 포함하는 조작을 사용하는 것을 특징으로 하는 제1항 또는 제2항에 따른 화합물의제조방법.
    상기 식에서 Ar 및 n은 제1항에서의 의미와 같다.
  7. Ar, n, Z1, Z2, Z4, Z5, Z6및 R3가 알킬카르복실레이트기를 나타낼 때 상기 일반식(Ⅰ)의 화합물의 가수분해 반응을 포함하는 조작을 사용하는 것을 특징으로 하는 제1항 또는 제2항에 따른 화합물의 제조방법.
  8. Ar, n, Z1, Z2, Z4, Z5, Z6및 R3가 제1항에서의 의미와 같으며, 치환체 R1, R2, R3및 R4가 카르복실 라디칼을 나타내는 상기 일반식(Ⅰ)의 화합물과 아민과의 반응을 포함하는 조작을 사용하는 것을 특징으로 하는 제1항 또는 제2항에 따른 화합물의 제조방법.
  9. 하기 일반식(Ⅸ)의 화합물의 환원 반응을 포함하는 조작을 사용하는 것을 특징으로 하는 제1항 또는 제2항에 따른 화합물의 제조방법.
    상기 식에서 Ar, Z1, Z2, Z4, Z5, Z6, R3및 n은 제1항에 있어서의 의미와 같다.
  10. 불안증의 치료를 위한 의약품의 제조, 특히 정신안정제 및/또는 불안해소제의 제조 및, 억압, 금단증후군, 인식 장해 및 고혈압의 치료를 위한 의약품의 제조를 위한, 제1항 내지 제5항중 어느 한 항에 따른 일반식(Ⅰ)의 유도체 및 그들의 생리학적으로 수용가능한 염의 이용.
  11. 제약학적으로 수용가능한 부형제에 부가하여 제1항 내지 제4항중 어느 한 항에 따른 일반식(Ⅰ)의 적어도 하나의 유도체 또는 그의 생리학적으로 수용가능한 염의 적어도 하나를 포함하는 것을 특징으로 하는 제약학적 조성.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920001213A 1991-01-28 1992-01-28 아릴(또는 헤테로아릴) 피페라지닐알킬아졸 유도체 및 그의 제조방법 및 그의 의약품으로의 이용 KR0135969B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9100923A FR2672052B1 (fr) 1991-01-28 1991-01-28 Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
FR9100923 1991-01-28

Publications (2)

Publication Number Publication Date
KR920014804A true KR920014804A (ko) 1992-08-25
KR0135969B1 KR0135969B1 (ko) 1998-04-25

Family

ID=9409103

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920001213A KR0135969B1 (ko) 1991-01-28 1992-01-28 아릴(또는 헤테로아릴) 피페라지닐알킬아졸 유도체 및 그의 제조방법 및 그의 의약품으로의 이용

Country Status (17)

Country Link
US (2) US5292739A (ko)
EP (1) EP0497659B1 (ko)
JP (1) JPH0745496B2 (ko)
KR (1) KR0135969B1 (ko)
AT (1) ATE136547T1 (ko)
AU (1) AU658389B2 (ko)
CA (1) CA2060090A1 (ko)
DE (1) DE69209679T2 (ko)
DK (1) DK0497659T3 (ko)
ES (1) ES2042385B1 (ko)
FR (1) FR2672052B1 (ko)
GR (1) GR3020437T3 (ko)
HU (1) HU219909B (ko)
NO (1) NO180539C (ko)
RU (1) RU2088582C1 (ko)
YU (1) YU48180B (ko)
ZA (1) ZA92534B (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665161B1 (fr) * 1990-07-26 1992-11-27 Esteve Labor Dr Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments.
FR2665160A1 (fr) * 1990-07-26 1992-01-31 Esteve Labor Dr Nouveaux derives de 1-diphenylmethylpiperazine, leur preparation et leur application en tant que medicaments.
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5712392A (en) * 1990-12-28 1998-01-27 Neurogen Corporation Certain 4-piperidine- and piperazinoalkyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
JPH09505029A (ja) * 1993-07-19 1997-05-20 藤沢薬品工業株式会社 ドパミン受容体作動薬、５−ＨＴ受容体拮抗薬あるいはα▲下１▼受容体拮抗薬として有用なベンズイミダゾール誘導体
FR2712808B1 (fr) * 1993-11-25 1996-02-16 Esteve Labor Dr Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique .
US5418236A (en) * 1993-12-23 1995-05-23 Ortho Pharmaceutical Corporation Anxiolytic aroyl piperidinyl and piperazinylacyl pyrroles
DE4425144A1 (de) * 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
ES2117934B1 (es) * 1994-07-29 1999-04-01 Esteve Labor Dr Tetrahidropiridinas (0 4-hidroxipiperidinas) alquilazoles.
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
US6355659B1 (en) 1994-07-29 2002-03-12 Laboratorios Del Dr. Esteve, S.A. 4-(4-Chlorophenyl)-1236-tetrahydro-1(1H-124-triazol-1-yl)butty)pyrideine and salts thereof; pharmaceutical compositions and method of treating psychoses utilizing same
US5618816A (en) * 1995-03-02 1997-04-08 Bristol-Myers Squibb Company Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines
ES2099031B1 (es) * 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
JP4108747B2 (ja) * 1995-07-13 2008-06-25 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 治療薬としてのピペラジン誘導体
FR2742052B1 (fr) * 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
FR2763950B1 (fr) * 1997-06-02 2002-09-20 Esteve Labor Dr 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
ES2125206B1 (es) * 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
ES2167276B1 (es) * 2000-10-20 2003-04-01 Esteve Labor Dr Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
ES2329356T3 (es) 2002-06-12 2009-11-25 Chemocentryx, Inc. Derivados de piperazina 1-arilo-4-sustituidos utilizados como antagonistas de ccr1 para el tratamiento de enfermedades inflamatorias e inmunitarias.
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
FR2877005A1 (fr) * 2004-10-22 2006-04-28 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
KR100654328B1 (ko) 2005-08-26 2006-12-08 한국과학기술연구원 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법
GB2435827A (en) * 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted piperazine compounds for the treatment of food related disorders
KR100882925B1 (ko) * 2007-06-14 2009-02-10 한국과학기술연구원 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
JP2016500084A (ja) * 2012-11-26 2016-01-07 リアオニン エミー バイオロジカル ファーマシューティカル カンパニー リミテッドＬｉａｏｎｉｎｇ Ｅｍｍｙ Ｂｉｏｌｏｇｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ 含窒素ベンゾ複素五員環基ピペリジン又はピペラジン誘導体及びその作製方法並びに薬剤組成物
EP2924033B1 (en) * 2012-11-26 2019-02-27 Shenyang Haiwang Biotechnology Co., Ltd Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
GB1117068A (en) * 1965-12-15 1968-06-12 Acraf S-triazole-[4,3-a]-pyridine derivatives and processes for their preparation
US3468882A (en) * 1966-10-07 1969-09-23 Sterling Drug Inc Phenylhydrazone derivatives as intermediates for preparing indoles
GB1189064A (en) * 1967-05-01 1970-04-22 Sterling Drug Inc Indole Derivatives
US3491098A (en) * 1967-05-29 1970-01-20 Sterling Drug Inc 1-((imidazolyl)-lower-alkyl)-4-substituted-piperazines
US3472855A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((benz(g)-indolyl)-lower-alkyl)-4-substituted-piperazines
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
DE2143730A1 (de) * 1971-09-01 1973-03-08 Byk Gulden Lomberg Chem Fab Substituierte pyridine, verfahren zu deren herstellung und sie enthaltende arzneimittel
DE3101502A1 (de) * 1981-01-19 1982-08-26 Basf Ag, 6700 Ludwigshafen Phenylpiperazinderivate von hetarylphenolen und hetarylanilinen, ihre hersttellung und diese enthaltendetherapeutische mittel
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
US4547499A (en) * 1984-05-10 1985-10-15 The Upjohn Company 2,4-Dihydro-2(omega-aminoalkyl)-1H-[1,2,4]triazolo[3,4-c]benzoxazin-1-one anti-allergy drug compounds, compositions and use
US4772604A (en) * 1986-02-27 1988-09-20 Duphar International Research B.V. Phenyl-substituted (N-piperazinyl) methylazoles for treating affections in the central nervous system
IT1230703B (it) * 1989-01-26 1991-10-29 Luso Farmaco Inst Derivati imidazolonici ad attivita' antiipertensiva, loro metodi di preparazione e composizioni farmaceutiche che li contengono.
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
DE3923045A1 (de) * 1989-07-13 1991-01-17 Merck Patent Gmbh Indolderivate

Also Published As

Publication number Publication date
FR2672052A1 (fr) 1992-07-31
NO920348D0 (no) 1992-01-27
CA2060090A1 (fr) 1992-07-29
DE69209679D1 (de) 1996-05-15
ATE136547T1 (de) 1996-04-15
US5292739A (en) 1994-03-08
HU219909B (hu) 2001-09-28
DK0497659T3 (da) 1996-07-15
FR2672052B1 (fr) 1995-05-24
US5382586A (en) 1995-01-17
EP0497659A1 (fr) 1992-08-05
AU1047992A (en) 1992-07-30
YU48180B (sh) 1997-07-31
ES2042385B1 (es) 1994-08-01
GR3020437T3 (en) 1996-10-31
YU8292A (sh) 1995-03-27
KR0135969B1 (ko) 1998-04-25
EP0497659B1 (fr) 1996-04-10
HUT60265A (en) 1992-08-28
AU658389B2 (en) 1995-04-13
JPH0745496B2 (ja) 1995-05-17
JPH04312584A (ja) 1992-11-04
ZA92534B (en) 1992-10-28
ES2042385A1 (es) 1993-12-01
RU2088582C1 (ru) 1997-08-27
DE69209679T2 (de) 1996-10-10
NO920348L (no) 1992-07-29
NO180539B (no) 1997-01-27
NO180539C (no) 1997-05-07
HU9200262D0 (en) 1992-04-28

Similar Documents

Publication Publication Date Title
KR920014804A (ko) 아릴 (또는 헤테로아릴) 피페라지닐알킬아졸 유도체 및 그의 제조방법 및 그의 의약품으로의 이용
JP3084537B2 (ja) アリール（又はヘテロアリール）ピペラジニルブチルアゾール誘導体の製造方法
CA1238321A (en) Anti-virally active pyridazinamines
KR920701167A (ko) 약제학적 활성 화합물
CA2445568A1 (en) Triazole-derived kinase inhibitors and uses thereof
PL142880B1 (en) Method of obtaining novel imidazole derivatives
FI102535B1 (fi) Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 1,3,5-trisubstituoituja pyratsolijohdannaisia
KR950032138A (ko) 벤즈이미다졸, 이 화합물을 함유하는 약제학적 조성물 및 이의 제조방법
HRP950532A2 (en) Apolipoprotein-b synthesis inhibitors
EP0196005B1 (de) Pyridazinone, ihre Herstellung und diese Verbindungen enthaltende Arzneimittel
HU194242B (en) Process for production of derivatives of pirrolobenzimidasole and containing thereof medical preparatives
FR2523582A1 (fr) Nouvelles 1h-pyrazolo(1,5-a)pyrimidines substituees, utiles notamment comme medicaments anti-inflammatoires et analgesiques, et procede pour leur preparation
HU211599A9 (en) Derivatives of benzimidazole and their use as antihistamines
NZ207914A (en) Indeno-pyridazinones and pharmaceutical compositions
AU702931B2 (en) Antipsychotic 4-(1H-indolyl-1-yl)-1-substituted piperidine derivatives
CN102227219A (zh) 取代的吡唑化合物
PH27056A (en) Ú5(6) (1H-azole-1-ylmethyl) benzimidazole
AU612236B2 (en) 6-oxo-4,5-dihydro-pyridazine derivatives, a process for their preparation and medicaments containing these compounds
CA2156409A1 (en) Quinolone derivatives as dopamine d4 ligands
KR870010039A (ko) 카르보스티릴 유도체 및 그의 염, 및 혈소판 유착 억제용 약학 조성물
CS250249B2 (en) Method of imidazole's tricyclic derivatives production
KR870010043A (ko) 헤테로고리로 치환된 벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 제약조성물
EP0064704B1 (en) 4-aminomethyl-5-acyl-1,3-dihydro-2h-imidazol-2-ones
WO1988002749A1 (en) Novel 2-mercaptobenzimidazole derivatives, process for their preparation, and anti-ulceric agents containing them as effective ingredients
IE52886B1 (en) 4-oxymethyl-5-acyl-1,3-dihydro-2h-imidazol-2-ones

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010104

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee